News brief
On 2026-04-15, according to Xiniu Data, Aomingxingcheng completed Series A financing, raising RMB 100 million. Investors were co-lead investor Shenzhen City Hecheng Biotechnology Industry Private Equity Investment Fund Partnership (Limited Partnership), co-lead investor Fujian Capital, Shenzhen Futiantaiping Medical Jiankang Private Equity Investment Fund Partnership (Limited Partnership), Kaiheng Investment and others. The company is a provider of biological intelligent infrastructure.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年4月15日，据烯牛数据报道，奥明星程完成A轮融资，金额1亿人民币。投资方为深圳市合成生物产业私募股权投资基金合伙企业（有限合伙）、复健资本领投、深圳福田太平医疗健康私募股权投资基金合伙企业（有限合伙）、开恒投资等。该公司为生物智能基础设施提供商。